GleamWall
中文EN

ATOS ATOSSA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1488039 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-14.8%
TTM EPS YoY31.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-96.9%
ROA-82.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.8%
Debt / equity0.00x
Current ratio5.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$21.18M$14.12M
SG&A expense$15.96M$13.50M
Operating income-$37.14M-$27.62M
Pretax income-$34.77M-$25.50M
Income tax$0$0
Net income-$34.77M-$25.50M
EBITDA-$37.12M-$27.60M
EPS (basic)-4.04-3.04
EPS (diluted)-4.04-3.04
Weighted avg. shares (diluted)8.61M8.39M
Balance sheet
Cash & equivalents$41.30M$71.08M
Current assets$45.62M$74.46M
Total assets$47.61M$76.44M
Current liabilities$8.26M$4.97M
Total liabilities$8.26M$4.97M
Shareholders' equity$39.35M$71.48M
Shares outstanding8.61M8.61M
Cash flow statement
Operating cash flow-$29.76M-$21.03M
Capital expenditure$23,000$19,000
Free cash flow-$29.79M-$21.05M
Investing cash flow-$23,000-$19,000
Financing cash flow$0$3.67M
Depreciation & amortization$16,000$17,000
Stock-based compensation$2.65M$2.29M
Share buybacks—$0

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.